Medications

Odomzo approved for recurring basal cell carcinoma

(HealthDay)—Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat basal cell carcinoma skin cancer that has returned despite surgery or radiation.

Medications

FDA approves odomzo for recurring basal cell carcinoma

(HealthDay)—Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat patients with locally advanced basal cell carcinoma that has returned despite surgery or radiation, or who are not candidates ...

Neuroscience

Two case reports of rare stiff person syndrome

Two female patients achieved clinical remission from the rare, debilitating neurological disease called stiff person syndrome (SPS, which can be marked by a "tin soldier" gait) after an autologous (from your own body) stem ...

Medications

First cannabis-derived drug authorised for France

France has for the first time approved prescription use of a drug derived from cannabis—a mouth spray used to treat multiple sclerosis (MS) symptoms, the government said Thursday.

page 2 from 4